Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US

Published:2021-07-09 Issue:7 Volume:4 Page:e2116357
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Bhattacharya Kaustuv¹²,Bentley John P.¹²,Ramachandran Sujith¹²,Chang Yunhee³,Banahan Benjamin F.¹²,Shah Ruchit⁴,Bhakta Nickhill⁵,Yang Yi¹²

Affiliation:

1. Center for Pharmaceutical Marketing and Management, University of Mississippi School of Pharmacy, University

2. Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University

3. Department of Nutrition and Hospitality Management, University of Mississippi, University

4. Pharmerit International, Bethesda, Maryland

5. Department of Global Pediatric Medicine, St Jude Children’s Research Hospital, Memphis, Tennessee

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2781731/bhattacharya_2021_oi_210489_1624993485.89531.pdf

Reference42 articles.

1. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework.;Roy;Am Health Drug Benefits,2015

2. Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.;Chen;Med Oncol,2017

3. Economic and clinical impact of multiple myeloma to managed care.;Cook;J Manag Care Pharm,2008

4. Trends in overall survival and costs of multiple myeloma, 2000-2014.;Fonseca;Leukemia,2017

5. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.;Petrucci;Tumori,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation;Frontiers in Hematology;2024-09-11

2. Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland;PharmacoEconomics - Open;2024-09-06

3. Phase-Based and Lifetime Health System Costs of Care for Patients Diagnosed with Leukemia and Lymphoma: A Population-Based Descriptive Study;Current Oncology;2024-07-25

4. Trends and Disparities in Treatment and Control of Atherosclerotic Cardiovascular Disease in US Adults, 1999 to 2018;Journal of the American Heart Association;2024-05-07

5. Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia;Journal of the American Geriatrics Society;2024-03-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3